Tau seeding in cases of multiple sclerosis.


Journal

Acta neuropathologica communications
ISSN: 2051-5960
Titre abrégé: Acta Neuropathol Commun
Pays: England
ID NLM: 101610673

Informations de publication

Date de publication:
11 10 2022
Historique:
received: 24 06 2022
accepted: 08 09 2022
entrez: 11 10 2022
pubmed: 12 10 2022
medline: 14 10 2022
Statut: epublish

Résumé

Relapsing remitting multiple sclerosis (MS) is an inflammatory demyelinating disorder of the central nervous system that in many cases leads to progressive MS, a neurodegenerative disease. Progressive MS is untreatable and relentless, and its cause is unknown. Prior studies of MS have documented neuronal accumulation of phosphorylated tau protein, which characterizes another heterogeneous group of neurogenerative disorders, the tauopathies. Known causes of tauopathy are myriad, and include point mutations within the tau gene, amyloid beta accumulation, repeated head trauma, and viral infection. We and others have proposed that tau has essential features of a prion. It forms intracellular assemblies that can exit a cell, enter a secondary cell, and serve as templates for their own replication in a process termed "seeding." We have previously developed specialized "biosensor" cell systems to detect and quantify tau seeds in brain tissues. We hypothesized that progressive MS is a tauopathy, potentially triggered by inflammation. We tested for and detected tau seeding in frozen brain tissue of 6/8 subjects with multiple sclerosis. We then evaluated multiple brain regions from a single subject for whom we had detailed clinical history. We observed seeding outside of MS plaques that was enriched by immunopurification with two anti-tau antibodies (HJ8.5 and MD3.1). Immunohistochemistry with AT8 and MD3.1 confirmed prior reports of tau accumulation in MS. Although larger studies are required, our data suggest that progressive MS may be considered a secondary tauopathy.

Identifiants

pubmed: 36221144
doi: 10.1186/s40478-022-01444-2
pii: 10.1186/s40478-022-01444-2
pmc: PMC9552360
doi:

Substances chimiques

Amyloid beta-Peptides 0
Prions 0
tau Proteins 0

Types de publication

Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

146

Subventions

Organisme : NIA NIH HHS
ID : RF1 AG059689
Pays : United States

Informations de copyright

© 2022. The Author(s).

Références

Neuron. 2016 Nov 23;92(4):796-812
pubmed: 27974162
Mol Ther. 2022 Apr 6;30(4):1484-1499
pubmed: 35007758
Acta Neuropathol Commun. 2021 May 26;9(1):99
pubmed: 34039426
Brain Pathol. 2015 May;25(3):350-64
pubmed: 25904048
Proc Natl Acad Sci U S A. 2016 Dec 13;113(50):E8187-E8196
pubmed: 27911827
Neuropathol Appl Neurobiol. 1994 Apr;20(2):103-10
pubmed: 8072641
Annu Rev Neurosci. 2008;31:247-69
pubmed: 18558855
Clin Neuropathol. 1996 Jan-Feb;15(1):22-5
pubmed: 8998852
Acta Neuropathol. 2009 May;117(5):583-9
pubmed: 19288121
Elife. 2018 Jul 10;7:
pubmed: 29988016
Proc Natl Acad Sci U S A. 2014 Oct 14;111(41):E4376-85
pubmed: 25261551
Nat Rev Neurol. 2012 Nov 5;8(11):647-56
pubmed: 23007702
Lancet. 2008 Oct 25;372(9648):1502-17
pubmed: 18970977
Acta Neuropathol. 2010 May;119(5):591-600
pubmed: 20306268
Acta Neuropathol. 2018 Nov;136(5):691-697
pubmed: 30219940
Acta Neuropathol. 2021 Jul;142(1):57-71
pubmed: 33830330
Ann Neurol. 2011 Feb;69(2):292-302
pubmed: 21387374
Neuron. 2014 Jun 18;82(6):1271-88
pubmed: 24857020
Acta Neuropathol Commun. 2021 Nov 2;9(1):177
pubmed: 34727983
Brain. 2008 Jul;131(Pt 7):1736-48
pubmed: 18567922
Nature. 2021 Oct;598(7880):359-363
pubmed: 34588692
Front Neurosci. 2018 Apr 24;12:267
pubmed: 29740275
Mult Scler. 2020 Jul;26(8):876-886
pubmed: 31682184
Neuron. 1999 Nov;24(3):507-10
pubmed: 10595503
Ann Neurol. 1997 Sep;42(3):356-9
pubmed: 9307257
Lancet Neurol. 2021 Jun;20(6):470-483
pubmed: 33930317

Auteurs

Michael S LaCroix (MS)

Center for Alzheimer's and Neurodegenerative Diseases, Peter O'Donnell Jr. Brain Institute, NL10.120, University of Texas Southwestern Medical Center, 6000 Harry Hines Blvd., Dallas, TX, 75390, USA.

Hilda Mirbaha (H)

Center for Alzheimer's and Neurodegenerative Diseases, Peter O'Donnell Jr. Brain Institute, NL10.120, University of Texas Southwestern Medical Center, 6000 Harry Hines Blvd., Dallas, TX, 75390, USA.
Department of Pathology, UT Southwestern Medical Center, Dallas, TX, USA.

Ping Shang (P)

Department of Pathology, UT Southwestern Medical Center, Dallas, TX, USA.

Stephanie Zandee (S)

Centre de Recherche du Centre Hospitalier de l'Université de Montréal (CRCHUM), Neuroimmunology Research Laboratory, Montreal, Quebec, H2X 0A9, Canada.
Department of Neurosciences, Faculty of Medicine, Université de Montreal, Montreal, Quebec, H3T 1J4, Canada.

Chan Foong (C)

Department of Pathology, UT Southwestern Medical Center, Dallas, TX, USA.

Alexandre Prat (A)

Centre de Recherche du Centre Hospitalier de l'Université de Montréal (CRCHUM), Neuroimmunology Research Laboratory, Montreal, Quebec, H2X 0A9, Canada.
Department of Neurosciences, Faculty of Medicine, Université de Montreal, Montreal, Quebec, H3T 1J4, Canada.

Charles L White (CL)

Department of Pathology, UT Southwestern Medical Center, Dallas, TX, USA.

Olaf Stuve (O)

Department of Neurology, UT Southwestern Medical Center, Dallas, TX, USA.
Neurology Section, VA North Texas Health Care System, Dallas, TX, USA.

Marc I Diamond (MI)

Center for Alzheimer's and Neurodegenerative Diseases, Peter O'Donnell Jr. Brain Institute, NL10.120, University of Texas Southwestern Medical Center, 6000 Harry Hines Blvd., Dallas, TX, 75390, USA. marc.diamond@utsouthwestern.edu.
Department of Neurology, UT Southwestern Medical Center, Dallas, TX, USA. marc.diamond@utsouthwestern.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH